Antiviral Drugs Market by Mechanism of Action (Fusion Inhibitors, DNA Polymerases, Protease Inhibitors, Reverse Transcriptase Inhibitors, and Others), Target Indication (Human Immunodeficiency Virus Infection, Hepatitis, Coronavirus Infection, Herpes Simplex Virus Infection, Cytomegalovirus Infection, Influenza, and Others), Type of Drug Target (Virus Targets and Host Targets), Type of Therapy (Monotherapy and Combination Therapy) and Key Geographies (North America, Europe, Asia-Pacific, Latin America, MENA, and RoW): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    September 2022

  • Pages
    245

  • View Count
    784

Example Insights

Antiviral-Drugs-Market-Context-thumb Antiviral-Drugs-Market-List-of-Approved-Antiviral-Drugs-thumb Antiviral-Drugs-Market-Different-Dosing-Regimens-thumb Antiviral-Drugs-Market-List-of-Clinical-Stage-thumb
Antiviral-Drugs-Market-Distribution-by-Type-of-Dosage-thumb Antiviral-Drugs-Market-Partnerships-and-Collaborations-thumb Antiviral-Drugs-Market-Funding-and-Investments-thumb Antiviral-Drugs-Market-Porter’s-Five-Forces-Analysis-thumb
Antiviral-Drugs-Market-Likely-Growth-Scenarios-thumb Antiviral-Drugs-Market-Opportunity-thumb    

Overview

Infectious diseases are known to be one of the top 10 leading causes of deaths, worldwide.  In-fact, more than 40 million people are affected by various types of infectious diseases annually. An article published in The Lancet journal reported that COVID-19 alone caused death of over 18 million people in 2020. Further, it has been reported that human immunodeficiency virus (HIV) is anticipated to be the cause for 6.5 million deaths globally, by 2030. Over the past few years, a number of antiviral drugs targeting a myriad of infectious diseases, including human immunodeficiency virus (HIV) infection, hepatitis, herpes simplex virus (HSV) infection, cytomegalovirus (CMV) infection, influenza, coronavirus infection (COVID-19) and others, have received approvals from various regulatory authorities, globally. However, it is important to note that, currently, the approved antiviral drugs (around 80) are capable of targeting only 10 of the 220 known viruses that are responsible for causing multiple life-threatening infectious diseases in humans. Further, several antiviral drugs are being evaluated across multiple clinical trials for the treatment of various infectious diseases. Moreover, post the onset of the COVID-19 pandemic, extensive research is being conducted to evaluate the safety and efficacy of novel antiviral therapeutics.

The antiviral therapeutic development is fraught with several challenges, including emergence of drug resistance in viruses (as viruses can frequently mutate their genome) and concerns related to drug safety and efficacy. In order to address the aforementioned concerns, several industry stakeholders have been actively leading the R&D efforts for the development of effective antiviral therapeutics against the known viral targets. The COVID-19 pandemic also exposed the lack of effective antiviral therapeutics that can be used for the treatment of re-emerging or emerging viral diseases; this has created opportunities for the development of novel antiviral drugs that can be effective against multiple viruses. Presently, more than 375 companies are engaged in the development of over 420 early and late-stage antiviral drugs, worldwide. These stakeholders have established multiple partnerships and collaborations in order to advance the development of various pipeline candidates. Moreover, in order to fund product development initiatives in this domain, various private and public sector investors have invested around USD 5.5 billion across multiple instances. Driven by the increasing demand for safe and effective antivirals, ongoing pace of innovation in this field, recent partnership activity and sufficient financial support from investors, the antiviral drugs market is anticipated to witness substantial growth in the mid to long-term.

Scope of the Report

The ‘Antiviral Drugs Market, 2022-2035: Distribution by Mechanism of Action (Fusion Inhibitors, DNA Polymerases, Protease Inhibitors, Reverse Transcriptase Inhibitors and Others), Target Indication (Human Immunodeficiency virus Infection,Coronavirus Infection, Hepatitis, Herpes Simplex Virus Infection, Cytomegalovirus Infection, Influenza, and Others), Type of Drug Target (Virus Targets and Host Targets), Type of Therapy (Monotherapy and Combination Therapy) and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2022-2035’ report features an extensive study of the current market landscape and future potential of the antiviral drugs market. The study also includes an in-depth analysis, highlighting the capabilities of antiviral drug developers engaged in this domain. Amongst other elements, the report features:

  • A general overview of the antiviral drugs, along with information on types of viruses and viral diseases, different mechanism of action of antiviral drugs and characteristics and advantages offered by the antiviral drugs. The chapter concludes with a discussion on the challenges associated with the development of antiviral drugs and future prospects in this domain.
  • A detailed assessment of the current market landscape of commercially available antiviral drugs, based on several relevant parameters, such as year of approval, type of dosage form (tablets, capsules, liquids, powders and others /unspecified), type of molecule (small molecules, biologics), type of target virus (DNA virus and RNA virus), route of administration (oral, intravenous, subcutaneous, intramuscular and others / unspecified), dosing frequency, mechanism of action (polymerase inhibition, protease inhibition, reverse transcriptase inhibition, nonnucleoside reverse transcriptase inhibition, integrase strand transfer inhibition, nucleoside reverse transcriptase inhibition, NS5A inhibition, CYP3A inhibition, neuraminidase inhibition, glycoprotein inhibition, immunostimulation, interferon alpha stimulation and viral fusion protein inhibition) and target indication (human immunodeficiency virus infection, hepatitis C infection, hepatitis B infection, herpes simplex virus infection, influenza virus infection, cytomegalovirus infection, coronavirus infection, ebolavirus infection and other indications). In addition, it provides details on the antiviral drug developers, along with analyses based on their year of establishment, company size, geographical location and leading players (in terms of number of approved antiviral drugs). 
  • A detailed assessment of the current market landscape of clinical-stage antiviral drugs, based on several relevant parameters, such as phase of development (phase I, phase I/II, phase II, phase II/III and phase III), type of molecule (small molecules, biologics), type of dosage form (tablets, capsules, liquids, powders and others /unspecified), route of administration (oral, intravenous, subcutaneous, intramuscular and others / unspecified), target indication (coronavirus infection, human immunodeficiency virus infection, hepatitis B infection, influenza virus infection, hepatitis C infection, respiratory syncytial virus infection, human papillomavirus infection, herpes simplex virus infection and other indications), type of developer (industry and industry / non-industry), type of therapy (monotherapy and combination therapy), target patient segment, mechanism of action (viral replication inhibition, anti-inflammation, immunostimulants, viral spike protein inhibition, interleukin receptor antagonists, polymerase inhibition, protease inhibition, viral entry inhibition, nucleoside reverse transcriptase inhibition, fusion protein inhibition, capsid protein inhibition, toll-like receptor antagonists, nonnucleoside reverse transcriptase inhibition, tyrosine kinase inhibition, viral core protein inhibition, Janus Kinases inhibition and HIV integrase inhibition), type of target virus (DNA virus and RNA virus) and number of doses. In addition, it provides details on the companies engaged in the development of clinical-stage antiviral drugs, based on their year of establishment, company size, location of headquarters and leading players (in terms of number of clinical-stage drugs).
  • An analysis of partnerships that have been inked by stakeholders engaged in this domain, since 2019, covering instances of clinical trial agreements, R&D agreements, product development and commercialization agreements, manufacturing agreements, product development agreements, commercialization agreements, acquisitions and mergers, product licensing agreements, supply agreements, manufacturing and commercialization agreements, product development and distribution agreements, technology licensing agreements, manufacturing and distribution agreements, distribution agreements and others. Further, the partnership activity in this domain has been analyzed based on several relevant parameters, such as year of partnership, type of partnership, target indication, type of target virus, type of partner, most active players (in terms of number of partnerships) and regional distribution of collaborations. 
  • A detailed analysis of investments that have been made into companies engaged in the antiviral drugs domain, since 2019, capturing instances of venture capital financing, capital raised from IPOs and subsequent public offerings, grants, debts and other equity.  
  • A qualitative analysis of the five competitive forces, including threats for new entrants, bargaining power of drug developers, bargaining power of buyers, threats of substitute products and rivalry among existing competitors under an insightful Porter’s Five Forces framework.
  • Elaborate profiles of prominent players engaged in development of antiviral drugs, featuring a brief overview of the company, details on its product portfolio and recent developments with an informed future outlook. 

One of the key objectives of the report was to evaluate the current market size and the future potential associated with the antiviral drugs market, over the coming decades. We have provided informed estimates of the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as  mechanism of action (fusion inhibitors, DNA polymerases, protease inhibitors, reverse transcriptase inhibitors and others), target indication (human immunodeficiency virus infection,coronavirus infection, hepatitis, herpes simplex virus infection, cytomegalovirus infection, influenza, and others), type of drug target (virus targets and host targets), type of therapy (monotherapy and combination therapy) and key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the market’s evolution.

Key Questions Answered

  • Who are the key players that have marketed their proprietary antiviral drugs?
  • Who are the leading players currently engaged in the development of clinical-stage antiviral drugs?
  • Which popular disease indications are being targeted by antiviral drugs?
  • What type of partnership models are commonly adopted by industry stakeholders?
  • Who are the key investors supporting research and development related to antiviral drugs? 
  • What are the key value drivers that are likely to influence the evolution of the antiviral drugs market?
  • How is the current and future market opportunity, related to antiviral drugs likely to be distributed across key market segments?

Contents

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Overview of Antiviral Drugs
3.2. Types of Viruses and Viral Diseases
3.3. Mechanism of Action of Antiviral Drugs
3.4. Characteristics of Antiviral Drugs
3.5. Advantages of Antiviral Drugs
3.6. Challenges Associated with Development of Antiviral Drugs
3.7. Key Facts and Future Perspectives of Antiviral Drugs

4. MARKET LANDSCAPE: APPROVED ANTIVIRAL DRUGS
4.1. Approved Antiviral Drugs: Overall Market Landscape
4.1.1. Analysis by Year of Approval
4.1.2. Analysis by Type of Dosage Form
4.1.3. Analysis by Type of Molecule
4.1.4. Analysis by Type of Target Virus
4.1.5. Analysis by Route of Administration
4.1.6. Analysis by Dosing Frequency
4.1.7. Analysis by Target Indication
4.1.8. Analysis by Mechanism of Action

4.2. Approved Antiviral Drugs: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Geography (Region-wise)
4.2.4. Analysis by Geography (Country-wise)
4.2.5. Most Active Players: Analysis by Number of Approved Drugs

5. MARKET LANDSCAPE: CLINICAL ANTIVIRAL DRUGS
5.1. Clinical-stage Antiviral Drugs: Overall Market Landscape
5.1.1. Analysis by Phase of Development
5.1.2. Analysis by Type of Molecule
5.1.3. Analysis by Phase of Development and Type of Molecule
5.1.4. Analysis by Type of Dosage Form
5.1.5. Analysis by Route of Administration
5.1.6. Analysis by Target Indication
5.1.7. Analysis by Phase of Development and Target Indication
5.1.8. Analysis by Type of Developer
5.1.9. Analysis by Type of Therapy
5.1.10. Analysis by Target Patient Segment
5.1.11. Analysis by Mechanism of Action
5.1.12. Analysis by Type of Target Virus
5.1.13. Analysis by Number of Doses

5.2. Clinical-Stage Antiviral Drugs: Developer Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Geography (Region-wise)
5.2.4. Analysis by Geography (Country-wise)
5.2.5. Analysis by Company Size and Location of Headquarters
5.2.6. Most Active Players: Analysis by Number of Clinical-Stage Drugs

6. COMPANY PROFILES
6.1. AbbVie
6.1.1. Company Overview
6.1.2. Key Executives
6.1.3. Financial Information
6.1.4. Product Portfolio
6.1.5. Recent Developments and Future Outlook

6.2. AstraZeneca
6.2.1. Company Overview
6.2.2. Key Executives
6.2.3. Financial Information
6.2.4. Product Portfolio
6.2.5. Recent Developments and Future Outlook

6.3. Bristol-Myers Squibb
6.3.1. Company Overview
6.3.2. Key Executives
6.3.3. Financial Information
6.3.4. Product Portfolio
6.3.5. Recent Developments and Future Outlook

6.4. Genentech
6.4.1. Company Overview
6.4.2. Key Executives
6.4.3. Product Portfolio
6.4.4. Recent Developments and Future Outlook

6.5. Gilead Sciences
6.5.1. Company Overview
6.5.2. Key Executives
6.5.3. Financial Information
6.5.4. Product Portfolio
6.5.5. Recent Developments and Future Outlook

6.6. GlaxoSmithKline (GSK)
6.6.1. Company Overview
6.6.2. Key Executives
6.6.3. Financial Information
6.6.4. Product Portfolio
6.6.5. Recent Developments and Future Outlook

6.7. Johnson & Johnson
6.7.1. Company Overview
6.7.2. Key Executives
6.7.3. Financial Information
6.7.4. Product Portfolio
6.7.5. Recent Developments and Future Outlook

6.8. Merck
6.8.1. Company Overview
6.8.2. Key Executives
6.8.3. Financial Information
6.8.4. Product Portfolio
6.8.5. Recent Developments and Future Outlook

6.9. Novartis
6.9.1. Company Overview
6.9.2. Key Executives
6.9.3. Financial Information
6.9.4. Product Portfolio
6.9.5. Recent Developments and Future Outlook

6.10. Pfizer
6.10.1. Company Overview
6.10.2. Key Executives
6.10.3. Financial Information
6.10.4. Product Portfolio
6.10.5. Recent Developments and Future Outlook

6.11. Roche
6.11.1. Company Overview
6.11.2. Key Executives
6.11.3. Financial Information
6.11.4. Product Portfolio
6.11.5. Recent Developments and Future Outlook

6.12. ViiV Healthcare
6.12.1. Company Overview
6.12.2. Key Executives
6.12.3. Product Portfolio
6.12.4. Recent Developments and Future Outlook

7. PARTNERSHIPS AND COLLABORATIONS
7.1. Antiviral Drugs: Partnerships and Collaborations
7.1.1. Analysis by Year of Partnership
7.1.2. Analysis by Type of Partnership
7.1.3. Analysis by Year and Type of Partnership
7.1.4. Analysis by Target Indication
7.1.5. Analysis by Type of Target Virus
7.1.6. Analysis by Type of Partner
7.1.7. Most Active Players: Analysis by Number of Partnerships
7.1.8. Geographical Analysis
7.1.8.1. Intercontinental and Intracontinental Deals 
7.1.8.2. International and Local Deals 

8. FUNDING AND INVESTMENTS
8.1. Antiviral Drugs: Funding and Investments
8.1.1. Analysis by Year of Funding
8.1.2. Analysis of Amount Invested by Year
8.1.3 Analysis by Type of Funding 
8.1.4. Analysis of Amount Invested by Type of Funding 
8.1.5. Analysis by Target Indication 
8.1.6. Analysis by Type of Target Virus
8.1.7. Analysis by Type of Investor
8.1.8. Most Active Players: Analysis by Number of Instances
8.1.9. Most Active Players: Analysis by Amount Invested
8.1.10. Most Active Investors: Analysis by Number of Instances
8.1.11. Geographical Analysis
8.1.11.1. Analysis of Amount Invested by Region
8.1.11.2. Analysis of Amount Invested by Country

9. PORTER’S FIVE FORCES ANALYSIS
9.1. Chapter Overview
9.2. Methodology and Key Parameters
9.3. Porter’s Five Forces
9.3.1. Threat of New Entrants
9.3.2. Bargaining Power of End Users
9.3.3. Bargaining Power of Drug Developers
9.3.4. Threat of Substitute Products 
9.3.5. Rivalry Among Existing Competitors

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Forecast Methodology and Key Assumptions
10.2. Global Antiviral Drugs Market, 2022-2035
10.2.1. Antiviral Drugs Market: Distribution by Mechanism of Action, 2022 and 2035
10.2.1.1. Antiviral Drugs Market for Fusion Inhibitors, 2022-2035
10.2.1.2. Antiviral Drugs Market for DNA Polymerases, 2022-2035
10.2.1.3. Antiviral Drugs Market for Protease Inhibitors, 2022-2035
10.2.1.4. Antiviral Drugs Market for Reverse Transcriptase Inhibitors, 2022-2035
10.2.1.5. Antiviral Drugs Market for Other Mechanisms, 2022-2035

10.2.2. Antiviral Drugs Market: Distribution by Target Indication, 2022 and 2035
10.2.2.1. Antiviral Drugs Market for Human Immunodeficiency Virus Infection, 2022-2035
10.2.2.2. Antiviral Drugs Market for Hepatitis, 2022-2035
10.2.2.3. Antiviral Drugs Market for Coronaviruses Infection, 2022-2035
10.2.2.4. Antiviral Drugs Market for Herpes Simplex Virus Infection, 2022-2035
10.2.2.5. Antiviral Drugs Market for Cytomegalovirus Infection, 2022-2035
10.2.2.6. Antiviral Drugs Market for Influenza, 2022-2035
10.2.2.7. Antiviral Drugs Market for Other Target Indications, 2022-2035

10.2.3. Antiviral Drugs Market: Distribution by Type of Drug Target, 2022 and 2035
10.2.3.1. Antiviral Drugs Market for Virus Targets, 2022-2035
10.2.3.2. Antiviral Drugs Market for Host Targets, 2022-2035

10.2.4. Antiviral Drugs Market: Distribution by Type of Therapy, 2022 and 2035
10.2.4.1. Antiviral Drugs Market for Monotherapy, 2022-2035
10.2.4.2. Antiviral Drugs Market for Combination Therapy, 2022-2035
10.2.5. Antiviral Drugs Market: Distribution by Geography, 2022 and 2035
10.2.5.1. Antiviral Drugs Market in North America, 2022-2035
10.2.5.2. Antiviral Drugs Market in Europe, 2022-2035
10.2.5.3. Antiviral Drugs Market in Asia-Pacific, 2022-2035
10.2.5.4. Antiviral Drugs Market in Latin America, 2022-2035
10.2.5.5. Antiviral Drugs Market in MENA, 2022-2035
10.2.5.6. Antiviral Drugs Market in Rest of the World, 2022-2035

11. EXECUTIVE INSIGHTS
11.1. Chapter Overview
11.2. Pardes Biosciences
11.2.1. Company Snapshot
11.2.2. Interview Transcript: Sean Brusky, Chief Commercial Officer

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Overall Market Landscape of Approved Antiviral Drugs
Figure 2.2 Executive Summary: Overall Market Landscape of Clinical-stage Antiviral Drugs
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Funding and Investments
Figure 2.5 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Types of Viruses
Figure 3.2 Mechanism of Action of Antiviral Drugs
Figure 4.1 Approved Antiviral Drugs: Distribution by Year of Approval
Figure 4.2 Approved Antiviral Drugs: Distribution by Type of Dosage Form
Figure 4.3 Approved Antiviral Drugs: Distribution by Type of Molecule
Figure 4.4 Approved Antiviral Drugs: Distribution by Type of Target Virus
Figure 4.5 Approved Antiviral Drugs: Distribution by Route of Administration
Figure 4.6 Approved Antiviral Drugs: Distribution by Dosing Frequency
Figure 4.7 Approved Antiviral Drugs: Distribution by Target Indication
Figure 4.8 Approved Antiviral Drugs: Distribution by Mechanism of Action
Figure 4.9 Approved Antiviral Drugs Developers: Distribution by Year of Establishment
Figure 4.10 Approved Antiviral Drugs Developers: Distribution by Company Size
Figure 4.11 Approved Antiviral Drugs Developers: Distribution by Geography (Region-wise)
Figure 4.12 Approved Antiviral Drugs Developers: Distribution by Geography (Country-wise)
Figure 4.13 Most Active Players: Distribution by Number of Approved Drugs
Figure 5.1 Clinical Antiviral Drugs: Distribution by Phase of Development
Figure 5.2 Clinical Antiviral Drugs: Distribution by Type of Molecule
Figure 5.3 Clinical Antiviral Drugs: Distribution by Phase of Development and Type of Molecule
Figure 5.4 Clinical Antiviral Drugs: Distribution by Type of Dosage Form
Figure 5.5 Clinical Antiviral Drugs: Distribution by Route of Administration
Figure 5.6 Clinical Antiviral Drugs: Distribution by Target Indication
Figure 5.7 Clinical Antiviral Drugs: Distribution by Phase of Development and Target Indication
Figure 5.8 Clinical Antiviral Drugs: Distribution by Type of Developer
Figure 5.9 Clinical Antiviral Drugs: Distribution by Type of Therapy
Figure 5.10 Clinical Antiviral Drugs: Distribution by Target Patient Segment
Figure 5.11 Clinical Antiviral Drugs: Distribution by Mechanism of Action
Figure 5.12 Clinical Antiviral Drugs: Distribution by Type of Target Virus
Figure 5.13 Clinical Antiviral Drugs: Distribution by Number of Doses
Figure 5.14 Clinical Antiviral Drugs Developers: Distribution by Year of Establishment
Figure 5.15 Clinical Antiviral Drugs Developers: Distribution by Company Size
Figure 5.16 Clinical Antiviral Drugs Developers: Distribution by Geography (Region-wise)
Figure 5.17 Clinical Antiviral Drugs Developers: Distribution by Geography (Country-wise)
Figure 5.18 Clinical Antiviral Drugs Developers: Distribution by Company Size and Location of Headquarters
Figure 5.19 Most Active Players: Distribution by Number of Clinical-Stage Drugs
Figure 7.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 7.4 Partnerships and Collaborations: Distribution by Target Indication
Figure 7.5 Partnerships and Collaborations: Distribution by Type of Target Virus
Figure 7.6 Partnerships and Collaborations: Distribution by Type of Partner
Figure 7.7 Most Active Players: Distribution by Number of Partnerships
Figure 7.8 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 7.9 Partnerships and Collaborations: International and Local Deals
Figure 8.1 Funding and Investments: Distribution by Year of Funding
Figure 8.2 Funding and Investments: Distribution of Amount Invested by Year
Figure 8.3 Funding and Investments: Distribution by Type of Funding
Figure 8.4 Funding and Investments: Distribution of Amount Invested by Type of Funding
Figure 8.5 Funding and Investments: Distribution by Target Indication
Figure 8.6 Funding and Investments: Distribution by Type of Target Virus
Figure 8.7 Funding and Investments: Distribution by Type of Investor
Figure 8.8 Most Active Players: Distribution by Number of Instances
Figure 8.9 Most Active Players: Distribution by Amount Invested
Figure 8.10 Most Active Investors: Distribution by Number of Instances
Figure 8.11 Funding and Investments: Distribution of Amount Invested by Region
Figure 8.12 Funding and Investments: Distribution of Amount Invested by Country
Figure 9.1 Antiviral Drugs: Porter’s Five Forces Analysis
Figure 10.1 Global Antiviral Drugs Market, 2022-2035 (USD Billion)
Figure 10.2 Antiviral Drugs Market: Distribution by Mechanism of Action, 2022 and 2035 (USD Billion)
Figure 10.3 Antiviral Drugs Market for Fusion Inhibitors, 2022-2035 (USD Billion)
Figure 10.4 Antiviral Drugs Market for DNA Polymerases, 2022-2035 (USD Billion)
Figure 10.5 Antiviral Drugs Market for Protease Inhibitors, 2022-2035 (USD Billion)
Figure 10.6 Antiviral Drugs Market for Reverse Transcriptase Inhibitors, 2022-2035 (USD Billion)
Figure 10.7 Antiviral Drugs Market for Other Mechanisms, 2022-2035 (USD Billion)
Figure 10.8 Antiviral Drugs Market: Distribution by Target Indication, 2022 and 2035 (USD Billion)
Figure 10.9 Antiviral Drugs Market for Human Immunodeficiency Virus Infection, 2022-2035 (USD Billion)
Figure 10.10 Antiviral Drugs Market for Hepatitis, 2022-2035 (USD Billion)
Figure 10.11 Antiviral Drugs Market for Coronavirus Infection, 2022-2035 (USD Billion)
Figure 10.12 Antiviral Drugs Market for Herpes Simplex Virus Infection, 2022-2035 (USD Billion)
Figure 10.13 Antiviral Drugs Market for Cytomegalovirus Infection, 2022-2035 (USD Billion)
Figure 10.14 Antiviral Drugs Market for Influenza, 2022-2035 (USD Billion)
Figure 10.15 Antiviral Drugs Market for Other Target Indications, 2022-2035 (USD Billion)
Figure 10.16 Antiviral Drugs Market: Distribution by Type of Drug Target, 2022 and 2035 (USD Billion)
Figure 10.17 Antiviral Drugs Market for Virus Targets, 2022-2035 (USD Billion)
Figure 10.18 Antiviral Drugs Market for Host Targets, 2022-2035 (USD Billion)
Figure 10.19 Antiviral Drugs Market: Distribution by Type of Therapy, 2022 and 2035 (USD Billion)
Figure 10.20 Antiviral Drugs Market for Monotherapy, 2022-2035 (USD Billion)
Figure 10.21 Antiviral Drugs Market for Combination Therapy, 2022-2035 (USD Billion)
Figure 10.22 Antiviral Drugs Market: Distribution by Geography, 2022 and 2035 (USD Billion)
Figure 10.23 Antiviral Drugs Market in North America, 2022-2035 (USD Billion)
Figure 10.24 Antiviral Drugs Market in Europe, 2022-2035 (USD Billion)
Figure 10.25 Antiviral Drugs Market in Asia-Pacific, 2022-2035 (USD Billion)
Figure 10.26 Antiviral Drugs Market in Latin America, 2022-2035 (USD Billion)
Figure 10.27 Antiviral Drugs Market in MENA, 2022-2035 (USD Billion)
Figure 10.28 Antiviral Drugs Market in Rest of the World, 2022-2035 (USD Billion)

List Of Tables

Table 4.1 List of Approved Antiviral Drugs
Table 4.2 List of Approved Antiviral Drug Developers
Table 5.1 List of Clinical-Stage Antiviral Drugs
Table 5.2 List of Clinical-Stage Antiviral Drug Developers
Table 6.1 AbbVie: Product Portfolio
Table 6.2 AbbVie: Recent Developments and Future Outlook
Table 6.3 AstraZeneca: Product Portfolio
Table 6.4 AstraZeneca: Recent Developments and Future Outlook
Table 6.5 Bristol-Myers Squibb: Product Portfolio
Table 6.6 Bristol-Myers Squibb: Recent Developments and Future Outlook
Table 6.7 Genentech: Product Portfolio
Table 6.8 Genentech: Recent Developments and Future Outlook
Table 6.9 Gilead Sciences: Product Portfolio
Table 6.10 Gilead Sciences: Recent Developments and Future Outlook
Table 6.11 GlaxoSmithKline: Product Portfolio
Table 6.12 GlaxoSmithKline: Recent Developments and Future Outlook
Table 6.13 Johnson & Johnson: Product Portfolio
Table 6.14 Johnson & Johnson: Recent Developments and Future Outlook
Table 6.15 Merck: Product Portfolio
Table 6.16 Merck: Recent Developments and Future Outlook
Table 6.17 Novartis: Product Portfolio
Table 6.18 Novartis: Recent Developments and Future Outlook
Table 6.19 Pfizer: Product Portfolio
Table 6.20 Pfizer: Recent Developments and Future Outlook
Table 6.21 Roche: Product Portfolio
Table 6.22 Roche: Recent Developments and Future Outlook
Table 6.23 ViiV Healthcare: Product Portfolio
Table 6.24 ViiV Healthcare: Recent Developments and Future Outlook
Table 7.1 Antiviral Drugs: List of Partnerships and Collaborations
Table 8.1 Antiviral Drugs: List of Funding and Investments
Table 12.1 Approved Antiviral Drugs: Distribution by Year of Approval
Table 12.2 Approved Antiviral Drugs: Distribution by Type of Dosage Form
Table 12.3 Approved Antiviral Drugs: Distribution by Type of Molecule
Table 12.4 Approved Antiviral Drugs: Distribution by Type of Target Virus
Table 12.5 Approved Antiviral Drugs: Distribution by Route of Administration
Table 12.6 Approved Antiviral Drugs: Distribution by Dosing Frequency
Table 12.7 Approved Antiviral Drugs: Distribution by Target Indication
Table 12.8 Approved Antiviral Drugs: Distribution by Mechanism of Action
Table 12.9 Approved Antiviral Drugs Developers: Distribution by Year of Establishment
Table 12.10 Approved Antiviral Drugs Developers: Distribution by Company Size
Table 12.11 Approved Antiviral Drugs Developers: Distribution by Geography (Region-wise)
Table 12.12 Approved Antiviral Drugs Developers: Distribution by Geography (Country-wise)
Table 12.13 Most Active Players: Distribution by Number of Approved Drugs
Table 12.14 Clinical Antiviral Drugs: Distribution by Phase of Development
Table 12.15 Clinical Antiviral Drugs: Distribution by Type of Molecule
Table 12.16 Clinical Antiviral Drugs: Distribution by Phase of Development and Type of Molecule
Table 12.17 Clinical Antiviral Drugs: Distribution by Type of Dosage Form
Table 12.18 Clinical Antiviral Drugs: Distribution by Route of Administration
Table 12.19 Clinical Antiviral Drugs: Distribution by Target Indication
Table 12.20 Clinical Antiviral Drugs: Distribution by Phase of Development and Target Indication
Table 12.21 Clinical Antiviral Drugs: Distribution by Type of Developer
Table 12.22 Clinical Antiviral Drugs: Distribution by Type of Therapy
Table 12.23 Clinical Antiviral Drugs: Distribution by Target Patient Segment
Table 12.24 Clinical Antiviral Drugs: Distribution by Mechanism of Action
Table 12.25 Clinical Antiviral Drugs: Distribution by Type of Target Virus
Table 12.26 Clinical Antiviral Drugs: Distribution by Number of Doses
Table 12.27 Clinical Antiviral Drugs Developers: Distribution by Year of Establishment
Table 12.28 Clinical Antiviral Drugs Developers: Distribution by Company Size
Table 12.29 Clinical Antiviral Drugs Developers: Distribution by Geography (Region-wise)
Table 12.30 Clinical Antiviral Drugs Developers: Distribution by Geography (Country-wise)
Table 12.31 Clinical Antiviral Drugs Developers: Distribution by Company Size and Location of Headquarters
Table 12.32 Most Active Players: Distribution by Number of Clinical-stage Drugs
Table 12.33 Partnerships and Collaborations: Distribution by Year of Partnership
Table 12.34 Partnerships and Collaborations: Distribution by Type of Partnership
Table 12.35 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 12.36 Partnerships and Collaborations: Distribution by Target Indication
Table 12.37 Partnerships and Collaborations: Distribution by Type of Target Virus
Table 12.38 Partnerships and Collaborations: Distribution by Type of Partner
Table 12.39 Most Active Players: Distribution by Number of Partnerships
Table 12.40 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 12.41 Partnerships and Collaborations: International and Local Deals
Table 12.42 Funding and Investments: Distribution by Year of Funding
Table 12.43 Funding and Investments: Distribution of Amount Invested by Year
Table 12.44 Funding and Investments: Distribution of by Type of Fundings
Table 12.45 Funding and Investments: Distribution of Amount Invested by Type of Funding
Table 12.46 Funding and Investments: Distribution by Target Indication
Table 12.47 Funding and Investments: Distribution by Type of Target Virus
Table 12.48 Funding and Investments: Distribution by Type of Investor
Table 12.49 Most Active Players: Distribution by Number of Instances
Table 12.50 Most Active Players: Distribution by Amount Invested
Table 12.51 Most Active Investors: Distribution by Number of Instances
Table 12.52 Funding and Investments: Distribution of Amount Invested by Region
Table 12.53 Funding and Investments: Distribution of Amount Invested by Country
Table 12.54 Global Antiviral Drugs Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.55 Antiviral Drugs Market: Distribution by Mechanism of Action, 2022 and 2035 (USD Billion)
Table 12.56 Antiviral Drugs Market for Fusion Inhibitors, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.57 Antiviral Drugs Market for DNA Polymerases, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.58 Antiviral Drugs Market for Protease Inhibitors, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.59 Antiviral Drugs Market for Reverse Transcriptase Inhibitors, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.60 Antiviral Drugs Market for Other Mechanisms, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.61 Antiviral Drugs Market: Distribution by Target Indication, 2022 and 2035 (USD Billion)
Table 12.62 Antiviral Drugs Market for Human Immunodeficiency Virus Infection, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.63 Antiviral Drugs Market for Hepatitis, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.64 Antiviral Drugs Market for Coronavirus Infection, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.65 Antiviral Drugs Market for Herpes Simplex Virus Infection, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.66 Antiviral Drugs Market for Cytomegalovirus Infection, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.67 Antiviral Drugs Market for Influenza, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.68 Antiviral Drugs Market for Other Target Indications, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.69 Antiviral Drugs Market: Distribution by Type of Drug Target, 2022 and 2035 (USD Billion)
Table 12.70 Antiviral Drugs Market for Virus Targets, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.71 Antiviral Drugs Market for Host Targets, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.72 Antiviral Drugs Market: Distribution by Type of Therapy, 2022 and 2035 (USD Billion)
Table 12.73 Antiviral Drugs Market for Monotherapy, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.74 Antiviral Drugs Market for Combination Therapy, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.75 Antiviral Drugs Market: Distribution by Geography, 2022 and 2035 (USD Billion)
Table 12.76 Antiviral Drugs Market in North America, 2022-2035 (USD Billion)
Table 12.77 Antiviral Drugs Market in Europe, 2022-2035 (USD Billion)
Table 12.78 Antiviral Drugs Market in Asia-Pacific, 2022-2035 (USD Billion)
Table 12.79 Antiviral Drugs Market in Latin America, 2022-2035 (USD Billion)
Table 12.80 Antiviral Drugs Market in MENA, 2022-2035 (USD Billion)
Table 12.81 Antiviral Drugs Market in Rest of the World, 2022-2035 (USD Billion)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 101 Therapeutics
  2. 30 TECHNOLOGY
  3. 3M
  4. 60 Degrees Pharmaceuticals (60P)
  5. Aardvark Therapeutics
  6. Aarhus University Hospital
  7. AB Science
  8. AbbVie
  9. AbCellera
  10. Abderrahmane Mami Hospital
  11. Acerta Pharma
  12. Acticor Biotech
  13. Adage Capital Management
  14. Adagio Therapeutics
  15. Adamis Pharmaceuticals
  16. Adimab
  17. Adjuvant Capital
  18. Advagene Biopharma
  19. Aevi Genomic Medicine (acquired by Avalo Therapeutics)
  20. Afyonkarahisar Health Sciences University
  21. AGC Biologics
  22. AgelessRx
  23. AiPharma
  24. Airway Therapeutics
  25. Aisling Capital
  26. Ajinomoto Bio-Pharma Services
  27. Albatross Capital
  28. Aldeyra Therapeutics
  29. Alexandria Venture Investments
  30. Algernon Pharmaceuticals
  31. Aligos Therapeutics
  32. AlloVir
  33. Ally Bridge Group
  34. Alnylam Pharmaceuticals
  35. Alphamab
  36. Altium Capital
  37. Altum Pharmaceuticals (subsidiary of BetterLife's)
  38. Amarex Clinical Research
  39. American Gene Technologies International
  40. amfAR
  41. Amgen
  42. Ampio Pharmaceuticals
  43. Amplyx Pharmaceuticals
  44. Amsterdam UMC
  45. Amyndas Pharmaceuticals
  46. Amzak Health
  47. ANA Therapeutics (acquired by NeuroBo Pharmaceuticals)
  48. Anaxago
  49. Andera Partners
  50. Angel Pharmaceuticals
  51. ANRS
  52. Ansun Biopharma
  53. Antios Therapeutics
  54. Antiva Biosciences
  55. Anzu Partners
  56. APCER Life Sciences
  57. APEIRON Biologics
  58. Apellis Pharmaceuticals
  59. Apex Services
  60. APICES
  61. Appili Therapeutics
  62. Applied Biology
  63. AptaBio Therapeutics
  64. Arbutus Biopharma
  65. ARCA Biopharma
  66. Ark Biosciences
  67. Arrowhead Pharmaceuticals
  68. ArrowMark Partners
  69. ARTIS Ventures
  70. Ascletis Pharma
  71. Ashfield Engage
  72. Ashvattha Therapeutics
  73. Aspire Capital Fund
  74. Assembly Biosciences
  75. Assistance Publique - Hôpitaux de Paris
  76. AstraZeneca
  77. Atea Pharmaceuticals
  78. Atreca
  79. Atriva Therapeutics
  80. aTyr Pharma
  81. Austria Wirtschaftsservice Gesellschaft (aws)
  82. Austrian Research Promotion Agency (FFG)
  83. Avantor
  84. Avego BioScience Capital (formerly known as Google Ventures)
  85. Avestria Ventures
  86. Avid Bioservices
  87. Azidus Brasil
  88. AzurRx BioPharma
  89. Bain Capital Life Sciences
  90. Banque Populaire
  91. Bausch + Lomb
  92. Bausch Health
  93. Bayer
  94. Baylor College of Medicine
  95. BDgene
  96. BDR Pharmaceuticals
  97. Beech Tree Labs
  98. BeiGene
  99. Beijing Defengrei Biotechnology
  100. Beijing Genova Biotech
  101. Beijing Tiantan Biological Products
  102. BerGenBio
  103. Beximco Pharmaceuticals
  104. Bharat Serums and Vaccines
  105. Bill & Melinda Gates Foundation
  106. Bill & Melinda Gates Medical Research Institute
  107. BioAge Labs
  108. BioAgilytix
  109. BIOCAD
  110. Bioclinica
  111. Biocon Biologics
  112. BioCryst Pharmaceuticals
  113. Biogen
  114. Biohaven Pharmaceuticals
  115. Biomedical Advanced Research and Development Authority (BARDA)
  116. Bionorica
  117. Biorasi
  118. Biotest
  119. Blade Therapeutics
  120. BlueSky Immunotherapies
  121. BNC Korea
  122. BNK Venture Capital
  123. Boan Biotech (a subsidiary of Luye Pharma Group)
  124. Boehringer Ingelheim
  125. Boxer Capital
  126. Bpifrance
  127. Brace Pharma Capital
  128. Brigham and Women's Hospital
  129. Brii Biosciences
  130. Bristol-Myers Squibb
  131. BronxCare Health System
  132. Bukwang Pharmaceutical
  133. Cadila Healthcare
  134. California Institute for Regenerative Medicine (CIRM)
  135. CAM Capital
  136. Cambridge Innovation Capital
  137. Canaan Partners
  138. Cancer Research Institute
  139. Can-Fite BioPharma
  140. Cardresearch
  141. Carelink Pharmaceutical
  142. Cascade Chemistry
  143. Celgene
  144. Celltrion
  145. Celonic
  146. Celularity
  147. Cenduit
  148. Cenexi
  149. Center for Drug Evaluation (CDE), Taiwan
  150. Chemical Diversity Research Institute
  151. Chime Biologics
  152. China Immunotech (Beijing) Biotechnology
  153. China Meheco
  154. China National Biotec Group
  155. China Venture Capital Fund
  156. Chinese Academy of Medical Sciences
  157. Chong Kun Dang Pharmaceutical
  158. CHRISTUS Health
  159. Chromis
  160. CICC Qide
  161. Cipla
  162. Clear Creek Bio
  163. Clearpool https://www.zoominfo.com/c/clinedem/532452984
  164. Clene Nanomedicine
  165. Clinedem
  166. CLINICAL RESEARCH VIET NAM SKILL TRAINING AND CONSULTING
  167. Clinical Service Center
  168. Clinical Trial Consultants
  169. Clinigen
  170. Clinipace
  171. Cocrystal Pharma
  172. Code Pharma
  173. Colorado Prevention Center
  174. Columbia University
  175. Copycat Sciences
  176. CORAT Therapeutics
  177. Cormorant Asset Management
  178. Coronavirus Immunotherapy Consortium (CoVIC)
  179. Corpometria Institute
  180. Corvus Pharmaceuticals
  181. Cosmo Pharmaceuticals
  182. Cota Capital
  183. CR Double-Crane
  184. CR-CP Life Science Fund
  185. Cromos Pharma
  186. CSL Behring
  187. CTI Clinical Trial and Consulting Services
  188. Cue Biopharma
  189. Curavit Clinical Research
  190. CytoDyn
  191. Daewoong Pharmaceuticals
  192. DalCor Pharmaceuticals
  193. DataMap
  194. Datametrix
  195. DCVC Bio
  196. Debiopharm
  197. Defense Advanced Research Projects Agency (DARPA)
  198. Defense Health Agency (DHA)
  199. Definvest
  200. Delos Capital
  201. Department of Health and Human Services
  202. Dermapharm
  203. Dicerna Pharmaceuticals
  204. dievini Hopp Biotech
  205. Diffusion Pharmaceuticals
  206. Domain Associates
  207. Dompé
  208. Dong-A ST
  209. Dongguan HEC TaiGen Biopharmaceuticals
  210. Door Pharmaceuticals
  211. Dr. Reddy’s Laboratories
  212. DSG
  213. Duke-NUS Medical School
  214. ECOGENE-21
  215. Edesa Biotech
  216. eFFECTOR Therapeutics
  217. EIC Fund
  218. Eiger BioPharmaceuticals
  219. Elaia
  220. Eli Lilly
  221. ELPEN
  222. EMD Serono
  223. Emergent BioSolutions
  224. Emergo Therapeutics
  225. Emory University
  226. EmphyCorp
  227. Enanta Pharmaceuticals
  228. ENYO Pharma
  229. EOM Pharmaceuticals
  230. Epiq Capital
  231. EQRx
  232. Equilab International
  233. Erasmus University Medical Center
  234. Erste Bank
  235. Eshmoun-Clinical Research
  236. Etana Biotechnologies
  237. Eunice Kennedy Shriver National Institute of Child Health and Human
  238. European Commission
  239. European Investment Bank
  240. European Union
  241. Everest Medicines
  242. Everest Venture Capital
  243. Evergreen Therapeutics
  244. Evive Biotech
  245. Excision BioTherapeutics
  246. Exvastat
  247. Eye & ENT Hospital of Fudan University
  248. Fab'entech
  249. Family First Medical Research Center
  250. Farmak
  251. Farmoquímica
  252. Federal Budget Institution of Science
  253. Central Research Institute of Epidemiology of Rospotrebnadzor
  254. Federal Government of Switzerland
  255. Federated Hermes
  256. FengChuan capital
  257. FHI Clinical
  258. Fidelity Management & Research
  259. First Light Asset Management
  260. First Wave BioPharma
  261. Flanders Innovation & Entrepreneurship
  262. Florence Healthcare
  263. Foresite Capital
  264. Forest Pharmaceuticals
  265. Fosun Pharma
  266. Founders Fund
  267. Fraunhofer Institute for Molecular Biology and Applied Ecology
  268. Community Regional Medical Center
  269. Frontier Biotechnologies
  270. Fujian Cosunter Pharmaceutical
  271. FUJIFILM Diosynth Biotechnologies
  272. FUJIFILM Pharmaceuticals
  273. FUJIFILM Toyama Chemical
  274. Gaingels
  275. Genentech
  276. Generation Bio
  277. Genexine
  278. Genoscience Pharma
  279. George Clinical
  280. German Federal Ministry of Education and Research
  281. Federal Ministry of Health (Germany)
  282. Ghent University Hospital
  283. Ghost Tree Capital
  284. GIC
  285. Gilead Sciences
  286. Global Response Aid (GRA)
  287. Golden Biotechnology
  288. GordonMD Global Investments
  289. Gorgas Memorial Institute for Health Studies (GMI)
  290. Government of Canada
  291. Government of France
  292. Grand Medical
  293. Granite Point Capital Management
  294. GreatPoint Ventures
  295. Green Sands Equity
  296. Grifols Therapeutics
  297. GSK
  298. Guangzhou Henovcom Bioscience
  299. Guangzhou Lupeng Pharmaceutical
  300. GV
  301. Halozyme Therapeutics
  302. Hamad Medical
  303. Hankang Capital
  304. Harbour BioMed
  305. HBM Healthcare Investments
  306. HealthCor Management
  307. Heartland Healthcare Capital
  308. Hebei Yanda Ludaopei Hospital
  309. Heidelberg ImmunoTherapeutics
  310. Heilongjiang ZBD Pharmaceutical
  311. HeNan Sincere Biotech
  312. Hengenix Biotech
  313. Hengxu Capital
  314. Hepion Pharmaceuticals
  315. HiFiBiO Therapeutics
  316. High-Tech Gründerfonds (HTGF)
  317. Hinova Pharmaceuticals
  318. HitGen
  319. Hongtao Capital
  320. HOOKIPA Pharma
  321. Hospital Alemão Oswaldo Cruz
  322. Hospital Casa de Saúde
  323. Hospital do Coração
  324. Hospital Israelita Albert Einstein
  325. Hospital Moinhos de Vento
  326. Hospital Santo Tomás
  327. Huadong Medicine
  328. Huahui Health
  329. Humanigen
  330. Huoshenshan Hospital
  331. hVIVO
  332. ICLPharma
  333. ICON
  334. IGM Biosciences
  335. ILTOO Pharma
  336. I-Mab Biopharma
  337. Immune Biosolutions
  338. Immune System Regulation (ISR)
  339. Immunic
  340. ImmunityBio
  341. ImmunoCellular Therapeutics
  342. Imuneks Farma
  343. Incepta Pharmaceuticals
  344. Incozen
  345. Incyte
  346. IndusAge Partners
  347. Infectious Disease Research Institute (IDRI)
  348. InnoStar Solutions
  349. Innovation Pharmaceuticals
  350. Innovent Biologics
  351. Inotrem
  352. Inova Health System
  353. Instat Clinical Research
  354. Institut Mérieux
  355. Institut Pasteur Korea
  356. International Maternal Pediatric Adolescent AIDS Clinical Trials Network
  357. InterX
  358. Invesco Developing Markets Fund
  359. Invus
  360. Ionis Pharmaceuticals
  361. IQVIA
  362. Israeli Ministry of Health (MoH)
  363. J.P. Morgan Securities
  364. Janssen
  365. Janus Henderson Investors
  366. Japan Agency for Medical Research and Development
  367. Jazz Pharmaceuticals
  368. Jena University Hospital
  369. Jiangsu Famaison Medical Technology
  370. Jiangsu Hansoh Pharmaceutical
  371. Jiangsu Hengrui Pharmaceuticals
  372. Jiangsu Pacific Meinuoke Bio-pharmaceutical
  373. Johns Hopkins University
  374. Johnson & Johnson
  375. JSS Medical Research
  376. Junshi Biosciences
  377. JX Partners
  378. KABS Laboratories
  379. Kamada
  380. Kansas State University
  381. Karyopharm Therapeutics
  382. Kedrion Biopharma
  383. KGbio
  384. Kinevant Sciences
  385. King Pharmaceuticals
  386. Kiniksa Pharmaceuticals
  387. Kintor Pharmaceutical
  388. Kite Pharma
  389. Korea Institute of Radiological & Medical Sciences
  390. Korea United Pharm
  391. Kowa
  392. KPM Tech
  393. Kreaxi
  394. KResearch
  395. KU Leuven
  396. Kukbo
  397. Kyorin Pharmaceutical
  398. Kyowa Kirin
  399. Kyushu University
  400. LabCorp Drug Development
  401. Labo'Life
  402. Laboratoire Boréaderme
  403. Laboratorios Silanes
  404. Lake Bleu Capital
  405. Laurent Pharma
  406. Leidos
  407. Lewis Katz School of Medicine
  408. LFB
  409. LianBio
  410. LifeSci Venture Partners
  411. Ligand Pharmaceuticals
  412. Light Chain Bioscience
  413. Lilly Asia Ventures (LAV)
  414. Lind Global Fund II
  415. Linear Clinical Research
  416. List Biological Laboratories
  417. Logos Capital
  418. Loreda Holdings
  419. Lumira Ventures
  420. Lung Biotechnology
  421. Lupin
  422. Luxna Biotech
  423. Luye Pharma
  424. M.D. Anderson Cancer Center
  425. M28 Capital
  426. mAbxience
  427. MacroGenics
  428. Shenzhen Maiwei BioTech
  429. Malakoff Humanis
  430. Mana Ventures
  431. Massachusetts General Hospital
  432. Matrix Partners China
  433. Mayo Clinic
  434. Athens Medical Society
  435. Medical University of Silesia
  436. Medical University of Vienna
  437. MediciNova
  438. MedImmune
  439. Medpace
  440. MedRegen
  441. Memorial Sloan Kettering Cancer Center
  442. Meneldor
  443. Merck
  444. Merck KGaA
  445. Merck Sharp & Dohme
  446. Mereo BioPharma
  447. MetrioPharm
  448. Metro International Biotech
  449. Ministry of Health (Morocco)
  450. MiNK Therapeutics
  451. Missouri State University
  452. Mithril
  453. ModeX Therapeutics
  454. Molecular Partners
  455. Institut de recherches cliniques de Montréal (IRCM)
  456. Moorim Capital
  457. Morningside Ventures
  458. Mount Sinai Health System
  459. Mylan
  460. Nabuboto
  461. Nanjing Sanhome Pharmaceutical
  462. NantKwest
  463. National Cancer Institute (NCI)
  464. National Center for Advancing Translational Sciences (NCATS)
  465. National Center for Global Health and Medicine
  466. National Heart, Lung, and Blood Institute (NHLBI)
  467. National Institute of Allergy and Infectious Diseases (NIAID)
  468. National Institute of Mental Health (NIMH)
  469. National Institute on Deafness and Other Communication Disorders (NIDCD)
  470. National Institutes of Health (NIH)
  471. National Research Council of Canada Industrial Research Assistance Program
  472. National University Hospital, Singapore
  473. National University of Singapore
  474. Natural Capital Investment Fund
  475. Naval Medical Research Unit 3 (NAMRU-3)
  476. Navigen
  477. NBank Capital
  478. NEAT ID Foundation
  479. Nektar Therapeutics
  480. NeoImmuneTech
  481. Neurelis
  482. NeuroActiva
  483. NeuroBo Pharmaceuticals
  484. NeuroRx
  485. NeuTec Pharma (acquired by Novartis)
  486. Neutrolis
  487. New Leaf Venture Partners
  488. Newsoara BioPharma
  489. NiKang Therapeutics
  490. Nobelpharma
  491. Noblewell
  492. Noorik Biopharmaceuticals
  493. Norwest Venture Partners
  494. Norwich Clinical Research Associates
  495. Nova Healthcare
  496. Novartis
  497. Novatek Pharmaceuticals
  498. Novo Holdings
  499. Nucorion Pharmaceuticals
  500. OBCTCD24
  501. Ohara Pharmaceutical
  502. Oklahoma State University
  503. Olatec Therapeutics
  504. Olive Tree Capital
  505. Omega Funds
  506. OncoImmune (acquired by Merck)
  507. Opera
  508. Ophirex
  509. OPKO Health
  510. OrbiMed
  511. OrbiMed Advisors
  512. Organicell Regenerative Medicine
  513. Osage University Partners
  514. Paidion Research (acquired by Premier Research)
  515. Palo Alto Pharmaceuticals
  516. Pardes Biosciences
  517. Partner Therapeutics
  518. PDS Biotechnology
  519. Peking University First Hospital
  520. Perceptive Advisors
  521. Petrovax
  522. Pfizer
  523. Pharco Pharmaceuticals
  524. Pharma Holdings
  525. Pharma Nord
  526. Pharmaceutical Solutions
  527. PharmaEssentia
  528. PharmaMar
  529. Pharmascience
  530. PHARMENTERPRISES
  531. Pharm-Olam
  532. Pharmsynthez
  533. Pivotal bioVenture Partners
  534. Plum Alley Investments
  535. Polaris Partners
  536. Polish Medical Research Agency (ABM)
  537. Pontifax
  538. Pontificia Universidad Católica de Chile
  539. Population Health Partners
  540. Population Health Research Institute (PHRI)
  541. POSCO Capital
  542. PPD
  543. Premji Invest
  544. Presight Capital
  545. PRISM BioLab
  546. Proteros Biostructures
  547. Prothione
  548. Proxima Clinical Research
  549. PT Lloyd Pharma
  550. PTC Therapeutics
  551. Pulmoquine Therapeutics
  552. Pulmotect
  553. Pulthera
  554. PureTech Health
  555. Q2 Solutions
  556. QbD Clinical
  557. Qilu Pharmaceutical
  558. Jiangxi Qingfeng Pharmaceutical
  559. Quercis Pharma
  560. R&G PharmaStudies
  561. RA Capital Management
  562. Rabin Medical Center
  563. Radboud University Medical Center
  564. Rawalpindi Medical University
  565. Guangdong Raynovent Biotech
  566. RedHill Biopharma
  567. Redmile Group
  568. Regeneron Pharmaceuticals
  569. Resolve Therapeutics
  570. Resverlogix
  571. Retrograde Investments
  572. RetroLead (Shanghai) BioPharma
  573. Reven Pharmaceuticals
  574. RevImmune
  575. ReViral (acquired by Pfizer)
  576. Revive Therapeutics
  577. Rhizen Pharmaceuticals
  578. Ride Wave Ventures
  579. Ridgeback Biotherapeutics
  580. Rigel Pharmaceuticals
  581. Roche
  582. Rock Springs Capital
  583. Rockefeller University
  584. Laboratorios Roemmers
  585. Roivant Sciences
  586. Romark
  587. R-Pharm
  588. RQ Biotechnology
  589. Ruijin Hospital
  590. Russian Academy of Medical Sciences
  591. SAB Biotherapeutics
  592. Sagent Pharmaceuticals
  593. Saigon Biopharma
  594. Saint Luke’s Mid America Heart Institute
  595. Samel
  596. Samsara BioCapital
  597. Samsung BioLogics
  598. Sanofi
  599. Sao Thai Duong Joint Stock Company
  600. SCiAN Services
  601. Scientific Center for Anti-infectious Drugs
  602. Sciwind Biosciences
  603. Scotmann Pharmaceuticals
  604. Scripps Research
  605. Sectoral Asset Management
  606. Selva Therapeutics
  607. Senhwa Biosciences
  608. Seoul Investment Partners
  609. SGS
  610. Shanghai East Hospital
  611. Shanghai Free Trade Zone Equity Investment Fund
  612. Shanghai Hepu Pharmaceutical
  613. Shanghai Pharmaceuticals
  614. Shanghai Tongren Hospital
  615. Shanxi Kangbao Biological Product
  616. Shaperon
  617. Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry (IBCh)
  618. Shenyang Tonglian Pharmaceutical
  619. Shenzhen Co-way Capital Services
  620. Shenzhen Share Capital
  621. Shin Poong Pharma
  622. Shionogi
  623. SIGA Technologies
  624. Sigma Gestion
  625. SigmaDrugs
  626. Simbec-Orion
  627. Singapore Clinical Research Institute (SCRI)
  628. Singlomics Biopharmaceuticals
  629. Sinopharm
  630. Sinopharm-CICC Capital
  631. Sirona Capital
  632. Sironax
  633. Sixty Degree Capital
  634. SmartPharm Therapeutics
  635. Smilegate Investment
  636. SOCAR Research
  637. Societe Generale
  638. Sofinnova Ventures
  639. Soleus Capital
  640. SomaLogic
  641. Soroka Medical Center
  642. Sorrento Therapeutics
  643. Sound Pharmaceuticals
  644. South Dakota Equity Partners
  645. Staidson Biopharma
  646. Statera Biopharma
  647. Stemedica Cell Technologies
  648. Sun Pharma
  649. Sunshine Lake Pharma (a subsidiary of HEC Pharm)
  650. SuperGene
  651. Supriya LifeScience
  652. Surveyor Capital
  653. Swiss National Science Foundation (SNSF)
  654. Synairgen
  655. Syneos Health
  656. TaiGen Biotechnology
  657. TaiMed Biologics
  658. TaiwanJ Pharmaceuticals
  659. Takeda Pharmaceuticals
  660. Telcon RF Pharmaceutical
  661. Telios Pharma
  662. Temasek
  663. The Medicines Patent Pool (MPP)
  664. The Montreal Health Innovations Coordinating Center (MHICC)
  665. The Supreme Council for the Arab-African Economy
  666. The Vienna Business Agency
  667. Theravance Biopharma
  668. Thermo Fisher Scientific
  669. Third People's Hospital of Shenzhen
  670. Thrombosis Research Institute
  671. Tiantu Capital
  672. TLC BioSciences
  673. Tokyo Metropolitan Komagome Hospital
  674. Tokyo Shinagawa Hospital
  675. Toscana Life Sciences
  676. Transcenta
  677. Tribe Capital
  678. Trinity Health
  679. TSB Therapeutics
  680. Tsinghua University
  681. Turn Therapeutics
  682. Turnstone Biologics
  683. Tychan
  684. U.S. Department of Defense
  685. U.S. Department of Health and Human Services (HHS)
  686. UCB Pharma
  687. United BioPharma
  688. United Medical Specialties
  689. United Nations Children’s Fund (UNICEF)
  690. United States Department of Defense
  691. UnitedHealth Group
  692. University Hospital, Basel, Switzerland
  693. Institut Universitaire de Cardiologie et de Pneumologie de Québec
  694. University Medical Center Goettingen
  695. University Medical Center of Johannes Gutenberg University Mainz
  696. University of Aarhus
  697. University of Alabama at Birmingham
  698. University of Arizona
  699. University of California
  700. University of Chicago
  701. University of Cologne
  702. University of Michigan
  703. University of Minnesota
  704. University of Nairobi
  705. University of Nebraska
  706. University of Oxford
  707. University of Pennsylvania
  708. University of Utah
  709. US Biotest
  710. US Government
  711. Utrecht University
  712. Valeant Pharmaceuticals (now Bausch Health)
  713. Valenta Pharm
  714. Valiant Capital Partners
  715. Vanderbilt University Medical Center
  716. Vasomune Therapeutics
  717. VBL Therapeutics
  718. Venrock Healthcare Capital Partners
  719. Veranex
  720. Verastem Oncology
  721. Verrica Pharmaceuticals
  722. Veru
  723. VetStem Biopharma
  724. Via Christi Research
  725. Vienna Insurance Group (VIG)
  726. Vietstar Biomedical Research
  727. Vigonvita Life Sciences
  728. ViiV Healthcare
  729. Viking Global Investors
  730. Vir Biotechnology
  731. ViralClear
  732. Viriom
  733. VirTrial
  734. Visterra
  735. Hainan Visum Pharmaceutical (acquired by TWi Pharmaceuticals)
  736. Wellington Management Company
  737. Westat
  738. Windtree Therapeutics
  739. WRVI Capital
  740. X-Chem
  741. XENOTHERA
  742. Xi'an Xintong Pharmaceutical Research
  743. Yuanta Investment
  744. Zhejiang Hisun Pharmaceutical

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com